| Disease | GROUPS FOR EITHER TOTAL SYMPTOM SCORES (P RANGE,.29-.90) OR MEAN INDIVIDUAL SYMPTOM SCORES ( P RANGE,.09-.93). THE TIME TO RESOLUTION OF SYMPTOMS WAS NOT STATISTICALLY DIFFERENT (P=.73).
ONSET. GROUP DEMGRAPHIC DISTRIBUTION WAS COMPARABLE FOR SEX, AGE, TIME FROM SYMPTOM ONSET TO ENROLLMENT IN THE STUDY, AVERAGE NUMBER OF COLDS PER YEAR, AND SMOKING HISTORY. NO STATISTICALLY SIGNIFICANT DIFFERENCE WAS OBSERVED BETWEEN TREATMENT
MEIER CURVES WERE USED TO ESTIMATE THE SURVIVAL FUNCTION OF TIME TO RESOLUTION IN EACH GROUP. THE WILCOXON RANK SUM TEST WAS USED TO COMPARE TIME TO RESOLUTION BETWEEN THE 2 GROUPS. 128 PATIENTS WERE ENROLLED WITHIN 24 HRS OF COLD SYMPTOMS
UNTIL THE END OF 14 DAYS, WHICHEVER CAME FIRST. SYMPTOMS(SNEEZING,NASAL DISCHARGE, NASAL CONGESTION, HEADACHE, SORE OR SCRATCHY THROAT, HOARSENESS, MUSCLE ACHES, AND COUGH) WERE SCORED SUBJECTIVELY BY THE PATIENT AND RECORDED DAILY. KAPLAN-
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DESIGN WAS USED. PATIENTS RECEIVED EITHER 100 MG OF E.PURPUREA (FREEZE-DRIED PRESSED JUICE FROM ARIAL PORTION OF THE PLANT) OR A LACTOSE PLACEBO 3 TIMES DAILY UNTIL COLD SYMPTOMS WERE RELIEVED OR |